A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials
2019
Journal of Cystic Fibrosis
Preserved Fulltext
Several treatment approaches in cystic fibrosis (CF) aim to correct CF transmembrane conductance regulator (CFTR) function; the efficacy of each approach is dependent on the mutation(s) present. A need remains for more effective treatments to correct functional deficits caused by the F508del mutation.
doi:10.1016/j.jcf.2019.04.014
pmid:31056441
fatcat:6nar6hl5grhzdbu3uayunrq5ma